Fermentalg (FALG) Q3 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 TU earnings summary
13 Jun, 2025Executive summary
Sales reached €9.7 million by end of September 2024, nearly tripling year-over-year from €3.3 million in 2023 and surpassing the previous high of €6.2 million in 2022.
Growth driven by a 30% increase in active customer accounts and higher average sales per customer.
Financial highlights
Sales for the first nine months of 2024 totaled €9.7 million, up from €3.3 million in the same period last year.
Company maintains its full-year sales target of approximately €12 million for 2024.
Outlook and guidance
Sales target for 2024 remains at around €12 million despite a challenging market environment.
Company continues to expand its customer base and diversify activities, with upcoming participation in major industry events.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fermentalg
- Record 2025 revenue and strategic investments position for strong growth and €20M target in 2026.FALG
Q4 2025 TU28 Jan 2026 - Revenue growth, new product launches, and global expansion set the stage for 2026.FALG
Q3 2025 TU7 Oct 2025 - H1 2025 revenue up 20% year-over-year, with strategic milestones and improved net loss.FALG
H1 202511 Sep 2025 - Sales up 20% in H1 2025, with new product approvals and no outstanding convertible debt.FALG
H1 2025 TU8 Jul 2025 - Sales up 2.7x and cash boosted by capital raise, with strategic partnerships accelerating.FALG
H1 202413 Jun 2025 - Record sales and a strengthened HuvePharma alliance drive Fermentalg's 2024 growth.FALG
Q2 2024 TU13 Jun 2025 - Q1 2025 revenue surged 36% as Fermentalg expands into new sustainable markets.FALG
Q1 2025 TU6 Jun 2025 - Revenue tripled and margins improved, setting a path to profitability by 2026.FALG
H2 20246 Jun 2025 - 2024 sales nearly tripled to €11.5M, with strong growth in new nutrition segments.FALG
Q4 2024 TU6 Jun 2025